Course of Esophageal Candidiasis and Outcomes of Patients at a Single Center

Patrick Hoversten, Fouad Otaki, David A. Katzka

Research output: Contribution to journalShort survey

2 Citations (Scopus)

Abstract

Candida infection in the gastrointestinal tract is most studied in immunocompromised patients. Patients without systemic immunodeficiency, however, may have esophageal candidiasis associated with antibiotic or steroid medication use, alcoholic consumption, diabetes mellitus, and esophageal stasis disorders such achalasia or scleroderma esophagus.1–5 This population has not been well studied. We aim to describe demographics, risk factors, and relevant clinical outcomes for patients with Candida esophagitis with an emphasis in systemically immunocompetent patients.

Original languageEnglish (US)
Pages (from-to)200-202.e1
JournalClinical Gastroenterology and Hepatology
Volume17
Issue number1
DOIs
StatePublished - Jan 1 2019
Externally publishedYes

Fingerprint

Candidiasis
Candida
Esophageal Achalasia
Esophagitis
Immunocompromised Host
Alcoholics
Gastrointestinal Tract
Diabetes Mellitus
Steroids
Demography
Anti-Bacterial Agents
Infection
Population

ASJC Scopus subject areas

  • Hepatology
  • Gastroenterology

Cite this

Course of Esophageal Candidiasis and Outcomes of Patients at a Single Center. / Hoversten, Patrick; Otaki, Fouad; Katzka, David A.

In: Clinical Gastroenterology and Hepatology, Vol. 17, No. 1, 01.01.2019, p. 200-202.e1.

Research output: Contribution to journalShort survey

@article{87d8efffcbd54f99b519f6375c4e0e5f,
title = "Course of Esophageal Candidiasis and Outcomes of Patients at a Single Center",
abstract = "Candida infection in the gastrointestinal tract is most studied in immunocompromised patients. Patients without systemic immunodeficiency, however, may have esophageal candidiasis associated with antibiotic or steroid medication use, alcoholic consumption, diabetes mellitus, and esophageal stasis disorders such achalasia or scleroderma esophagus.1–5 This population has not been well studied. We aim to describe demographics, risk factors, and relevant clinical outcomes for patients with Candida esophagitis with an emphasis in systemically immunocompetent patients.",
author = "Patrick Hoversten and Fouad Otaki and Katzka, {David A.}",
year = "2019",
month = "1",
day = "1",
doi = "10.1016/j.cgh.2018.04.035",
language = "English (US)",
volume = "17",
pages = "200--202.e1",
journal = "Clinical Gastroenterology and Hepatology",
issn = "1542-3565",
publisher = "W.B. Saunders Ltd",
number = "1",

}

TY - JOUR

T1 - Course of Esophageal Candidiasis and Outcomes of Patients at a Single Center

AU - Hoversten, Patrick

AU - Otaki, Fouad

AU - Katzka, David A.

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Candida infection in the gastrointestinal tract is most studied in immunocompromised patients. Patients without systemic immunodeficiency, however, may have esophageal candidiasis associated with antibiotic or steroid medication use, alcoholic consumption, diabetes mellitus, and esophageal stasis disorders such achalasia or scleroderma esophagus.1–5 This population has not been well studied. We aim to describe demographics, risk factors, and relevant clinical outcomes for patients with Candida esophagitis with an emphasis in systemically immunocompetent patients.

AB - Candida infection in the gastrointestinal tract is most studied in immunocompromised patients. Patients without systemic immunodeficiency, however, may have esophageal candidiasis associated with antibiotic or steroid medication use, alcoholic consumption, diabetes mellitus, and esophageal stasis disorders such achalasia or scleroderma esophagus.1–5 This population has not been well studied. We aim to describe demographics, risk factors, and relevant clinical outcomes for patients with Candida esophagitis with an emphasis in systemically immunocompetent patients.

UR - http://www.scopus.com/inward/record.url?scp=85057226533&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85057226533&partnerID=8YFLogxK

U2 - 10.1016/j.cgh.2018.04.035

DO - 10.1016/j.cgh.2018.04.035

M3 - Short survey

VL - 17

SP - 200-202.e1

JO - Clinical Gastroenterology and Hepatology

JF - Clinical Gastroenterology and Hepatology

SN - 1542-3565

IS - 1

ER -